Immune modulation of liver sinusoidal endothelial cells by melittin nanoparticles suppresses liver metastasis

Xiang Yu, Lu Chen, Jianqiao Liu, Bolei Dai, Guoqiang Xu, Guanxin Shen, Qingming Luo () and Zhihong Zhang ()
Additional contact information
Xiang Yu: Wuhan National Laboratory for Optoelectronics-Huazhong University of Science and Technology
Lu Chen: Wuhan National Laboratory for Optoelectronics-Huazhong University of Science and Technology
Jianqiao Liu: Wuhan National Laboratory for Optoelectronics-Huazhong University of Science and Technology
Bolei Dai: Wuhan National Laboratory for Optoelectronics-Huazhong University of Science and Technology
Guoqiang Xu: Wuhan National Laboratory for Optoelectronics-Huazhong University of Science and Technology
Guanxin Shen: Huazhong University of Science and Technology
Qingming Luo: Wuhan National Laboratory for Optoelectronics-Huazhong University of Science and Technology
Zhihong Zhang: Wuhan National Laboratory for Optoelectronics-Huazhong University of Science and Technology

Nature Communications, 2019, vol. 10, issue 1, 1-14

Abstract: Abstract Liver sinusoidal endothelial cells (LSECs) are responsible for the immunologic tolerance of liver which is a common site for visceral metastases, suggesting its potential role as an target for cancer immunotherapy. However, targeted modulation of LSECs is still not achieved thus far. Here, we report LSECs are specifically targeted and modulated by melittin nanoparticles (α-melittin-NPs). Intravital imaging shows that LSECs fluoresce within 20 s after intravenous injection of α-melittin-NPs. α-melittin-NPs trigger the activation of LSECs and lead to dramatic changes of cytokine/chemokine milieu in the liver, which switches the hepatic immunologic environment to the activated state. As a result, α-melittin-NPs resist the formation of metastatic lesions with high efficiency. More strikingly, the survival rate reaches 80% in the spontaneous liver metastatic tumor model. Our research provides support for the use of α-melittin-NPs to break LSEC-mediated immunologic tolerance, which opens an avenue to control liver metastasis through the immunomodulation of LSECs.

Date: 2019
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-019-08538-x Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:10:y:2019:i:1:d:10.1038_s41467-019-08538-x

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-019-08538-x

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().